OOIR: Observatory of International Research

Papers

(The TQCC of Endocrine-Related Cancer is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	110
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	66
Acknowledgement to reviewers	62
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	56
Metastatic neuroendocrine neoplasms of the breast: a systematic review	54
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance	40
Update on the genetics of paragangliomas	39
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	36
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study	34
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	34
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	31
NP-101 in Combination with Nivolumab and Ipilimumab in Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECs): A Pilot Study	31
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	31
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	29
Targeting growth hormone in cancer: future perspectives	29
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	27
Defining aging-associated factors that increase susceptibility to prostate cancer	27
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	26
Metabolically active brown adipose tissue in PPGL: an observational cohort study	24
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	23
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	23
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	21
PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	21
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	20
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	20

Determinants of False Positive Plasma Free Metanephrines and Methoxytyramine: The Role of Medications and Chronic Disease	20
Impact of sex hormones on development and progression in NEN: a new therapeutic target?	19
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	19
Peptide receptor radionuclide therapy in malignant insulinoma	18
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	17
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	17
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	16
Gender-affirming care and endocrine-related cancers	16
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	15
Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC	15
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	15
Whole-exome sequencing of rectal neuroendocrine tumors	15
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	14
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	14
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	13
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	13
Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma	13
Immunotherapy for endocrine tumours: a clinician’s perspective	13
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	13
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	12
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60	12
From bench to bedside in the sella: translational developments in pituitary tumour genetics	12
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	12
Acknowledgement to reviewers	12
Steroid profile in patients with breast cancer and in mice treated with mifepristone	12
Exploring stem cell biology in pituitary tumors and derived organoids	12
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	12
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	12
Acknowledgement to reviewers	12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
Clinical features of plurihormonal pituitary adenoma subtypes	11
Systems biology successes and areas for opportunity in prostate cancer	11
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2	10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	10
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	10
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	10
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer	10
NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors	10
Relationship between vascular density and microenvironment in medullary thyroid carcinoma	10
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	10
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC	10
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	10

Genetic disorders and insulinoma/glucagonoma	10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	10
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
Deiodinases in thyroid tumorigenesis	9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	9
In memoriam: Charis Eng MD PhD (1962–2024)	9
Beyond the three P’s: adrenal involvement in MEN1	9
Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model	9
Non-pituitary GH regulation of the tissue microenvironment	9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	8
MicroRNAs as regulators of tumor metabolism	8
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	8
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A	8
Surrogate molecular classification of LAR breast cancer in routine workflow	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	7
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	7
Chemoembolization using streptozotocin versus embolization in metastatic NETs	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	7
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	7
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	7
Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis	7
Acknowledgement to reviewers	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
Characterization of small intestinal neuroendocrine tumorlets	7
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	7
Rethinking paraganglioma management: distinct clinical pathways for head and neck versus other sites	7
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	7
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
Cryoablation of bone metastases in thyroid and adrenocortical cancers	7
Insulinomatosis: new aspects	7
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	7